18 and older, any sex, with Chronic Pain. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in the Brief Pain Inventory (BPI) Interference Score From Baseline, Over the 12-month Follow-up Period.Primary· Weighted average over 10 weeks, 6 months, and 12 months.
Change in the Brief Pain Inventory (BPI) interference score. Minimum value: 0. Maximum value: 10. Higher scores indicate worse functioning.
Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
4.8
± 0.1
Mobile LAMP Mindfulness-Based Intervention
4.5
± 0.1
Usual Care
5.2
± 0.1
Change in the Brief Pain Inventory (BPI) Intensity Score From Baseline, Over the 12-month Follow-up Period.Secondary· Weighted average over 10 weeks, 6 months, and 12 months.
Brief Pain Inventory (BPI) intensity score. Minimum value: 0. Maximum value: 10. Higher scores indicate more severe pain. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
4.7
± 0.1
Mobile LAMP Mindfulness-Based Intervention
4.6
± 0.1
Usual Care
5.1
± 0.1
Change in Physical Functioning Over the 12-month Follow-up Period Assessed by Mean Score on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile v.2.0 Measure of Physical FunctionSecondary· Weighted average over 10 weeks, 6 months, and 12 months.
Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile v.2.0 measure of physical function. Minimum value: 4. Maximum value: 20. Lower scores indicate worse physical functioning. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
13.3
± 0.1
Mobile LAMP Mindfulness-Based Intervention
13.3
± 0.1
Usual Care
12.7
± 0.1
Change in Anxiety Over the 12-month Follow-up Period Assessed by Mean Score on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile v.2.0 Measure of AnxietySecondary· Weighted average over 10 weeks, 6 months, and 12 months.
Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile v.2.0 measure of anxiety. Minimum value: 4. Maximum value: 20. Higher scores indicate worse anxiety. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
9.2
± 0.1
Mobile LAMP Mindfulness-Based Intervention
8.8
± 0.2
Usual Care
9.4
± 0.1
Change in Fatigue Over the 12-month Follow-up Period Assessed by Mean Score on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile v.2.0 Measure of FatigueSecondary· Weighted average over 10 weeks, 6 months, and 12 months.
Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile v.2.0 measure of fatigue. Minimum value: 4. Maximum value: 20. Higher scores indicate worse fatigue. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
12.9
± 0.2
Mobile LAMP Mindfulness-Based Intervention
12.7
± 0.2
Usual Care
13.5
± 0.2
Change in Sleep Disturbance Over the 12-month Follow-up Period Assessed by Mean Score on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile v.2.0 Measure of Sleep DisturbanceSecondary· Weighted average over 10 weeks, 6 months, and 12 months.
Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile v.2.0 measure of sleep disturbance. Minimum value: 4. Maximum value: 20. Higher scores indicate worse sleep disturbance. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
13.3
± 0.2
Mobile LAMP Mindfulness-Based Intervention
13.3
± 0.2
Usual Care
13.9
± 0.2
Change in Participation in Social Roles and Activities Over the 12-month Follow-up Period Assessed by Mean Score on the PROMIS-29 Profile v.2.0 Measure of Participation in Social Roles and ActivitiesSecondary· Weighted average over 10 weeks, 6 months, and 12 months.
PROMIS-29 Profile v.2.0 measure of participation in social roles and activities. Minimum value: 4. Maximum value: 20. Lower scores indicate greater participation in social roles and activities. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
12.0
± 0.2
Mobile LAMP Mindfulness-Based Intervention
11.9
± 0.2
Usual Care
11.0
± 0.1
Change in Depression Over the 12-month Follow-up Period Assessed by Score on the Eight-item Patient Health Questionnaire Depression Scale (PHQ8)Secondary· Weighted average over 10 weeks, 6 months, and 12 months.
Patient Health Questionnaire depression scale (PHQ8). Minimum value: 0. Maximum value: 24. Higher scores indicate greater depression. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
8.2
± 0.2
Mobile LAMP Mindfulness-Based Intervention
8.2
± 0.2
Usual Care
9.1
± 0.2
Change in Post Traumatic Stress Disorder (PTSD), Over the 12-month Follow-up Period, Assessed by Participants' Scores on the Post Traumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders - 5 (PCL-5)Secondary· Weighted average over 10 weeks, 6 months, and 12 months.
Post Traumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders - 5 (PCL-5). Minimum value: 0. Maximum value: 80. Higher scores indicate greater PTSD. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
22.8
± 0.6
Mobile LAMP Mindfulness-Based Intervention
22.7
± 0.6
Usual Care
24.9
± 0.6
Mean Global Improvement of Pain Score, Over the 12-month Follow-up PeriodSecondary· Weighted average over 10 weeks, 6 months, and 12 months.
Global impression of change scale from "much better" to "much worse". Minimum value: 1. Maximum value: 7. Higher scores indicate worse outcome. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
3.4
± 0.1
Mobile LAMP Mindfulness-Based Intervention
3.3
± 0.1
Usual Care
4.1
± 0.1
BPI Interference Score Responder AnalysisSecondary· Weighted average over 10 weeks, 6 months, and 12 months.
Change in Brief Pain Inventory (BPI) interference score over the 12-month follow-up period. Number with 30% improvement in BPI inference score. Change in the outcome measure operationalized as the weighted average of all of the time points during follow-up, adjusting for the baseline value prior to randomization.
Group
Value
95% CI
Mobile+Group LAMP Mindfulness-Based Intervention
89
Mobile LAMP Mindfulness-Based Intervention
109
Usual Care
56
Sponsor's own description
The long-term goal of this two-phase project is to reduce chronic pain and co-morbid conditions among Veterans, through scalable, non-pharmacologic evidence-based strategies that are "Veteran-Centric," designed to optimize engagement, adherence and sustainability, and are deliverable to large numbers of Veterans.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by United States Department of Defense
Last refreshed: 5 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04526158.